The Effects of 6-hydroxydopamine (6-OHDA) and Neuronal Nitric Oxide Synthase Inhibitor ( nNOSI) on Ability of Zebrafish to recover from parkinson’s disease-like.

Slides:



Advertisements
Similar presentations
How strong is the link between PD and exposure to pesticides Oct 21 Sarah Kim, Tanner Warren, Hyun Park, Khoi Nguyen.
Advertisements

The PARticulars of Parkinson’s Disease
PHL 437/Pharmacogenomics Fourth Lecture (Parkinson’s disease) By Abdelkader Ashour, Ph.D. Phone:
Parkinson’s Disease First described as the ‘shaking palsy’ by James Parkinson, this neurodegenerative plagues nearly 1 million Americans who have been.
Is it a neurodegenerative brain disorder that progresses slowly in most people.
What is Aging? Alzheimer’s Disease Parkinson’s Disease.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Erica Partridge Parkinson’s Disease. Definition Aetiology PD vs Parkinsonism Symptoms and signs Differentials Investigations Management Prognosis.
Motor Response Complications and Cycline-Dependent Kinase 5 (Cdk5) Neuroadaptations in an Animal Model of Parkinson’s Disease Heather Minkel Dr. Justin.
Innovations in Parkinson’s Diagnosis & Treatment: A Personal Story Dr. Kenneth E. Keirstead Excellence in Aging Care Symposium September 25-27, 2013.
Mostly Parkinson’s disease but also few other movement disorders due to diseases of the basal ganglia.
Neurotransmitters: Catecholamines & Acetylcholine Chapters 5 & 6 Catecholamines  Dopamine  Norepinephrine  Epinephrine Acetylcholine Serotonin Glutamate.
Aging Nervous System. Neurotrophic Factors Necessary for Maintenance of Neurons Neurotrophin function o Play role in development of NS o Interact with.
 Parkinson Disease (PD) is a disorder of the brain that causes a variety of movement problems.
 Parkinson’s Disease (PD) -progressive neurodegenerative disease affecting motor ability -third most common neurologic disorder of older adults.
The evolution of non-motor symptoms in patients with Parkinson’s disease treated with Duodopa intestinal gel Natalia Pritcan Doctor Jozsef Attila Szasz.
Improvement of life quality and non motor symptoms relief in patients with advanced Parkinson's disease. Natalia Prican Andra Oltean Doctor Jozsef Attila.
PARKINSON’S DISEASE BY: NICOLE MABARDI & SHAINA JOSEPH.
Non-motor symptoms of PD revealed in mice with reduced vesicular storage Tonya Taylor MSP Symposium May 29, 2009.
By: Alejandro Navarro and Andrea Ors. Content Introduction What is Parkinson's disease? What causes the disease? History Main symptoms Treatment Statistics.
By Katelyn Chaimson and Sean Guyot
Parkinson’s Disease Sheila Mulhern. Parkinson’s Disease Stats (PDF)  One million Americans live with Parkinson's disease, - more than the combined number.
Dopamine in CNC Abdulelah Nuqali Intern. Overview Introduction Biochemistry Dopamine receptors Dopaminergic pathways Summary 2.
Pathogenesis and pathology of parkinsonism
By Seamus Hogan.  Parkinsons disease is degenerative disorder of the central nervous system. it causes the dopamine to contain cells in the substantial.
Parkinson’s Disease Casey Wang
Emma Hahs, Brooke Armistead, Sarah Brown, Sok Kean Khoo Department of Cell and Molecular Biology, College of Liberal Arts and Sciences, Grand Valley State.
Parkinson's disease ♦ Is a neurodegenerative disorder ♦ Develops around age 50 * incidence rises with age * affects 1-2% of population > age 65 ♦ Higher.
PARKINSON’S DISEASE CHAMINDA UNANTENNE RN,MS,MSN.
“HEALTH IS THE BEST” In the name of God. WHAT IS IT? Parkinson's disease (PD) is a chronic and progressive movement disorder, meaning that symptoms.
Parkinson’s disease by Syed Baseeruddin Alvi (09).
Parkinson’s Disease.
Neurotransmitters.
Aubrey Hernandez Dr. Robert Haining Spring 2016
By the end of this section you will be able to …..
Lecture 3 Dr.Narmin Hussen
Parkinson's disease KRZYSZTOF NICPOŃ.
(vi) AMI+Rotenone H&E X 20
Zebrafish Research Data Analysis Choices.
Introduction There is an abundance of molecular, cellular, biochemical, animal model and human patient literature to support the concept that estrogen.
Zebrafish as an Animal Model for Movement Disorders
Effects of Estrogen and Nitric Oxide Deprivation on Late-Developing Zebrafish Heart Health Presented by: Brice Scott, Nicole Blixt, Jeff Nutter, Ian McFarland,
Zebrafish Research Data Analysis Choices.
Presented by: Connor Culley, Derek Emerson, and Chris Baker
Nitric Oxide (NO) and How it Regulates Motor Function
Investigating the role of Ca+2/calmodulin dependent kinase pathways
Estrogen and its Rescue Effects on 6-OHDA Treated Embryonic Zebrafish
Dopamine AND PD.
Dallas Wood Dylan griFFin matt Nicholson
Zebrafish Research Data Analysis Choices.
The effectiveness of producing hyperkinesia in zebrafish as a model for Parkinson's DISEASE Conor Snyder 2016 Biology; Biochemistry and Molecular Biology.
Treatment of Parkinson’s disease
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
Parkinson’s disease.
Justin Hayase MSTAR Presentation Guo Lab July 23,2009
Long Term Effects of Concussions
Alpha-synuclein in Parkinson's disease
Seratonin and Dopamine in the CNS
Parkinson’s Common neurodegenerative disorder ~10-20/1000
Volume 60, Issue 2, Pages (August 2001)
Sarah M Gibbs, James W Truman  Neuron 
Fred D. Lorenzetti, Douglas A. Baxter, John H. Byrne  Neuron 
Justin Hayase MSTAR Presentation Guo Lab July 23,2009
Yali Zhao, Ashok N Hegde, Kelsey C Martin  Current Biology 
Neurodegenerative diseases
Identification of Small Molecule Inhibitors that Distinguish between Non-Transferrin Bound Iron Uptake and Transferrin-Mediated Iron Transport  Jing Xu.
Postural, morphological and swim defects in Mn-exposed zebrafish larvae. Postural, morphological and swim defects in Mn-exposed zebrafish larvae. (A) Scheme.
Volume 25, Issue 22, Pages (November 2015)
Volume 16, Issue 3, Pages (March 1996)
HOW DOES EXPERIENCE AFFECT BEHAVIOUR AND MENTAL PROCESSES?
Presentation transcript:

The Effects of 6-hydroxydopamine (6-OHDA) and Neuronal Nitric Oxide Synthase Inhibitor ( nNOSI) on Ability of Zebrafish to recover from parkinson’s disease-like symptoms Meredith Baldasare ‘16, Joel Hoisington ‘15, and Bridgette Pouliot ’16 BI-420W-01 Seminar Research Presentation Biology Department Virginia Military Institute

Introduction Parkinson’s Disease (PD) is the 2nd most common neurodegenerative condition in the world. It is caused by the loss of dopaminergic neurons in the substantia nigra and presence of Lewy bodies in the remaining dopamine (DA) neurons. Dopamine is a catecholamine that regulates hormones, motor control and learning. Symptoms of PD include: shaking, rigidity, slowness of movement, difficulty walking, balance problems, dementia, depression, in addition to sensory, sleep, and emotional problems.

Introduction cont. Nitric oxide is a gaseous molecule that acts as an intracellular messenger for body functions such as: blood blow, platelet activity, and heart and neural/motor activity (Lorenc-Koci and Czarnecka, 2013). Neuronal nitric oxide synthase inhibitor (nNOSI) blocks nitric oxide synthesis which inhibits the dopamine pathway and causes Parkinson’s-like symptoms in zebrafish. 6-hydroxydopamine (6OHDA) is a neurotoxin that compromises dopamine neurons in the zebrafish (Parng et al., 2007). Zebrafish are a good model for our experiment because of their transparency and ability to treat them by changing their environment and have been established a a model for studying PD-like symptoms (Flinn et al., 2008).

Hypothesis If the zebrafish are treated with a co-treatment of 50μM of nNOSI and 500μM of 6OHDA, then motor deficiencies will be induced that resembles the effects of PD in humans (the listless condition). The longer the co-treatment the more difficult it will be for fish to recover from these motor deficiencies upon co-treatment cessation due to DA neuronal degeneration. Goal – to ultimately develop a zebrafish model of regenerative recovery from PD–like symptoms

Materials and Methods Zebrafish (6 days post-fertilization) were kept at 28.5°C in an incubator and their solutions that they lived in were changed out every 24 hours. Fish were counted in each well and were exposed to the treatment of either 50 µM nNOSI, 500 µM 6OHDA, or a co-treatment of both. The control fish were treated with ERS. Methylene blue was added to all solutions to keep microbes from growing. The “listless” condition was determined by whether or not the fish responded to probing with a pipet, irregular swimming patterns, if the fish demonstrated vestibular problems by sitting on it’s side, or not spontaneously swimming at all.

Materials and Methods Data analysis The percent of fish within a population that demonstrated the listless characteristics (PD-like symptoms) were determined at each 24 hour period during the assay. Data were analyzed for significant differences either by a z-test for two population proportions or for multiple proportions using a chi-square contingency table test followed by a Marascuilo's post hoc analysis

Results Figure 1 – Indicates the effects of various concentrations of nNOSI and its subsequent washout on the listless (PD-like symptoms) condition. A concentration of 50 µM elicits the maximum response over the first 24 hours of treatment. Also note that All fish recover from the listless condition after ERS washout (arrows).

Results Compare p values at 48 hours of treatment; use asterisks to indicate significant differences in survival rates. Figure 2 – Shows how the co-treatment (nNOSI + 6-OHDA) allows the fish to demonstrate PD-like symptoms with significantly greater survival than that of the single treatments (p< ---).

Results Do stats Figure 4 – Demonstrates the effect of prolonged co-treatment (nNOSI + 6OHDA) prior to ERS washout (arrows) on recovery from the listless (PD-like symptoms) condition. Note that the longer the treatment prior to washout the longer it takes the fish to recover.

Conclusions Co-treated fish survive longer than those treated in either nNOSI or 6-OHDA alone and is a better approach to establishing a regenerative recovery model. The longer the fish are exposed to the co-treatment (50uM nNOSI and 500uM of 6-OHDA) the slower their rate of recovery from PD-like symptoms after ERS washout.

Future Studies Further research could include a longer recovery period at 72 hours after ERS washout to determine if fish do slowly recover from the PD-like symptoms.

References Flinn L, Bretaud S, Lo C, Ingham PW, Bandmann O. J. 2008. Zebrafish as a new animal model for movement disorders. Neurochem. 106(5):1991-7 Lorenc-Koci E, Czarnecka A. 2013. Role of nitric oxide in the regulation of motor function. An overview of behavioral, biochemical and histological studies in animal models. Pharmacol Rep. 65(5):1043-55. Parng C, Roy NM, Ton C, Lin Y, McGrath P. 2007. Neurotoxicity assessment using zebrafish. J. Pharmacol Toxicol Methods. 55(1):103-12.

Acknowledgements COL. James Turner, Mrs. Julie Lozier, Branden Barbery, and the Virginia Military Institute Biology Department